Abstract: An electrical network includes feed-in means, loads, and a distribution network located therebetween which includes at least one dynamic isolator and busbars. The feed-in means and the loads together with associated busbars are disposed in groups which can be electrically interconnected or disconnected by the at least one dynamic isolator. The at least one dynamic isolator monitors the voltage on the busbars adjacent thereto for a voltage difference. In a normal state without a voltage difference, the at least one dynamic isolator electrically disconnects the groups from one another, and in the event of a voltage difference between the busbars adjacent thereto, the at least one dynamic isolator electrically connects the groups to one another.

Abstract: An electrical network is equipped with feed-in devices, loads, a distribution grid arranged therebetween, at least one semiconductor switch, and at least one electromechanical switch for separating a feed-in device or a load in the event of a fault. The feed-in devices and loads are arranged in groups which are connected together by a busbar and paired semiconductor switches. Each feed-in device and load can be separated from the grid by an electromechanical switch in the event of a fault, and the individual groups of feed-in devices and loads can be separated from one another by the semiconductor switches in the event of a fault in order to prevent cross currents on the busbar.

Abstract: An electric grid includes feed-ins, loads, and a distribution grid, which is arranged therebetween. The distribution grid comprises at least one busbar and at least one device for opening or closing a DC circuit. The at least one device includes an electric switch for opening or closing the DC circuit, a fault current detector, a trigger unit, a precharging device, and a control unit for automatically closing the electric switch after the precharging process. The electric switch opens the DC circuit via the trigger unit if a fault current is detected by the fault current detector, and the precharging device restores the voltage on the busbar prior to closing the electric switch.

Abstract: A circuit breaker device is for coupling a DC voltage branch to a positive and a negative conductor on a DC voltage bus. In an embodiment, the circuit breaker device includes a series circuit including a safety fuse and a unidirectional switch module. The switch module has a parallel circuit includes a controllable semiconductor switch element that is conductive in a first current direction and a diode that is conductive in the opposite current direction.

Abstract: A DC voltage switch includes a semiconductor-based electronically controllable switching device, a sensor provided upstream of the switching device for determining the DC voltage bus-side voltage level, a sensor provided downstream of the switching device for determining the DC voltage branch-side voltage level, a current sensor for determining current level and direction, a control device designed such that the direction and level of the current are determined, the flow of current is interrupted by the switching device when a first threshold value of the current level is exceeded, and when the first threshold value of the current level is exceeded in the reverse direction: the DC voltage bus-side voltage level is compared with the DC voltage branch-side voltage level, and the switching device is switched on upon a voltage difference being less than a voltage difference value.

Abstract: A switching device is for coupling a DC voltage branch to a DC voltage bus. The switching device includes a series circuit including a first switching module and a second switching module. A first diode is connected in parallel with the first semiconductor switching element and a second diode is connected in parallel with the second semiconductor switching element. A third semiconductor switching element is connected in parallel with the series circuit. A control device is connected to the first and second semiconductor switching elements, to the bridging semiconductor switching element, to the voltage sensor and to the current sensor. The control device is configured to, upon a first threshold value of the voltage being undershot and current flowing in an exceptional case, switch the bridging semiconductor switching element to the conducting state in order to facilitate a current flow from the DC voltage branch to the DC voltage bus.

Abstract: A method for calculating the contact state of an electrical switch is disclosed, In an embodiment, the method includes: collecting first input values for calculating the contact state in a first component of the electrical switch; collecting second input values for calculating the contact state in a second component of the electrical switch; and calculating the contact state of the electrical switch from the first input values and the second input values.

Abstract: A transdermal delivery device (10, 10?) includes at least one of a backing layer (14) and a removable release liner (16). An active layer (12, 12?) is supported by the backing layer and/or release liner. The active layer includes a polymer matrix, a therapeutically/cosmetically effective amount of an active agent dispersed in the polymer matrix, and a pressure sensitive adhesive, incorporated in the polymer matrix and/or adhered thereto. The polymer matrix includes a thermoplastic polyurethane polymer and optionally, a poly(meth)acrylate polymer. The thermoplastic polyurethane polymer includes the reaction product of: a first polyether polyol A having a molecular weight of at least 3000 daltons and/or a second polyether polyol B having a molecular weight of no more than 2500 daltons; a third polyol C having a molecular weight of up to 800 daltons and/or a chain extender; a polyisocyanate; and optionally a catalyst.

Abstract: The present invention provides a microgrid system. The microgrid system includes a microgrid bus, electrically connected to an external grid; microgrid branches, electrically connected to the microgrid bus; nanogrids, electrically connected to the microgrid branches; and microgrid protection devices, each of the microgrid protection devices including at least one of a protection device connected between the microgrid bus and the external grid, protection devices connected between the microgrid branches and the microgrid bus and protection devices connected between nanogrids and microgrid branches, each of the microgrid protection devices being configured to break at least one of an electrical connection between the microgrid bus and the external grid, electrical connections between the microgrid branches and the microgrid bus and an electrical connections between the nanogrids and the microgrid branches upon at least one of the external grid, the microgrid bus and the microgrid branches malfunctioning.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: The invention relates to a multilayer dosage form comprised of: a) a neutral core; b) an inner coating consisting of a methacrylate copolymer; c) an outer coating consisting of a copolymer of which 40 to 95% by weight is composed of radically polymerized C1 to C4 alkyl esters of acrylic acid or of methacrylic acid and of which 5 to 60% by weight is composed of (meth)acrylate monomers having an anionic group in the alkyl radical. The invention is characterized in that the inner coating is essentially comprised of a methacrylate copolymer, of which at least up to 90% by weight consists of (meth)acrylate monomers with neutral radicals, which, in accordance with DIN 53 787, has a minimum film formation temperature of no higher than 30° C., and which contains the pharmaceutical active substance in bound form.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: The invention relates to a system (1) for controlling an electrolytic reaction in a reaction medium, with the system (1) comprising a primary energy storage (10), an intermediate storage (30) and a control unit (50). The control unit of the system is adapted for transferring electrical energy from the primary energy storage into the intermediate storage, monitoring the state of charge of the intermediate storage, establishing an electric connection between the reaction medium and the intermediate storage when the state of charge of the intermediate storage is larger than or equal to a first threshold value, and interrupting an electric connection between the reaction medium and the intermediate storage when the state of charge of the intermediate storage is smaller than or equal to a second threshold value.

Abstract: The invention relates to a process for producing mouldings by injection moulding the steps in the process being a) melting and mixing of a (meth)acrylate copolymer composed of from 85 to 98% by weight of C1-C4-alkyl (meth)acrylates capable of free-radical polymerization and from 15 to 2% by weight of (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, with from 10 to 25% by weight of a plasticizer, and also from 10 to 50% by weight of a dryers [sic] and/or from 0.1 to 3% by weight of a release agent, and, where appropriate, with other conventional pharmaceutical additives or auxiliaries and/or with an active pharmaceutical ingredient, b) devolatilizing the mixture at temperatures of at least 120° C., thus reducing the content of the low-boiling constituents with a vapour pressure of at least 1.9 bar at 120° C. to not more than 0.5% by weight, and c) injecting the devolatilized mixture at a temperature of from 80 to 160° C.

Abstract: Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold.

Abstract: The invention relates to a multiparticulate drug form suitable for uniform release of an active pharmaceutical ingredient in the small intestine and in the large intestine, comprising at least two forms of pellets A and B which comprise an active pharmaceutical ingredient in the core and have different polymer coatings which determine the release of the active ingredient at different pH values, characterized in that pellet form A is provided with an inner polymer coating which enables continuous release of active ingredient, and has an outer enteric coating which rapidly dissolves above about pH 5.5, and pellet form B is provided with a polymer coating which, in the USP release test, releases less than 20% of the active ingredient at pH 6.8 in 6 hours and releases more than 50% of the active ingredient at pH 7.2 in 6 hours. The invention additionally relates to a process for producing the multiparticulate drug form and to the use of pellet forms A and B for producing the drug form.

Abstract: A swellable intermediate layer that includes a swellable material selected from the group of starch, starch derivatives such as pregelatinised starch, sodium carboxyethyl starch, sodium starch gycolate, cellulose, cellulose ethers such as HPMC, HPC, HEC MC, sodium carboxymethyl cellulose, carrageenans, aginates, pectins, xanthanes and their derivatives, guar gum, tragacanth, polyvinyl pyrrolidones and mixtures thereof, in a delayed-release, solid pharmaceutical formulation for peroral use. The formulation has a substrate containing an active substance, the swellable intermediate layer and a retarding coating layer for the adjustment of a release profile for the active substance which essentially permits complete release near the end.

Abstract: The invention relates to a multilayer dosage form comprised of: a) a neutral core; b) an inner coating consisting of a methacrylate copolymer; c) an outer coating consisting of a copolymer of which 40 to 95% by weight is composed of radically polymerized C1 to C4 alkyl esters of acrylic acid or of methacrylic acid and of which 5 to 60% by weight is composed of (meth)acrylate monomers having an anionic group in the alkyl radical. The invention is characterized in that the inner coating is essentially comprised of a methacrylate copolymer, of which at least up to 90% by weight consists of (meth)acrylate monomers with neutral radicals, which, in accordance with DIN 53 787, has a minimum film formation temperature of no higher than 30° C., and which contains the pharmaceutical active substance in bound form.